Last updated: March 8, 2026
Case Overview
Celgene Corporation filed a patent infringement lawsuit against Teva Pharmaceuticals USA, Inc. in the District of Delaware. The case involves U.S. Patent No. 7,192,863, which protects intellectual property related to Celgene’s pharmaceutical compositions. The litigation commenced on December 31, 2015, with the complaint accusing Teva of manufacturing and selling a generic version of Celgene’s product prior to patent expiry.
Core Legal Issues
- Patent infringement of U.S. Patent No. 7,192,863
- Validity and enforceability of the patent
- Non-infringement defenses raised by Teva
- Patent term and potential for patent term extension
Patent Details
| Patent Number |
Title |
Filing Date |
Issue Date |
Expiry Date |
Claims Summary |
| 7,192,863 |
"Pharmaceutical composition" |
August 14, 2006 |
March 20, 2007 |
March 20, 2027 |
Claims cover a specific composition of a drug used to treat hematological malignancies, including methods of manufacturing. |
The patent claims protection over a composition comprising a specific ratio of active ingredients, designed to improve treatment efficacy.
Timeline of Litigation
| Date |
Event |
Comments |
| December 31, 2015 |
Complaint filed |
Alleged infringement by Teva’s generic version of Revlimid (lenalidomide) |
| August 2016 |
Teva files motion for summary judgment |
Asserts patent invalidity and non-infringement |
| March 2018 |
Court denies motions; oral arguments held |
Continuing disputes over patent scope |
| July 2020 |
Settlement negotiations |
No public record of settlement or license agreement |
Legal Positions
Celgene
- Claims Teva’s generic release infringes the '863 patent
- Argues patent validity based on non-obviousness and novelty
- Seeks injunctive relief and damages for unauthorized sales
Teva
- Contends the patent claims are invalid under 35 U.S.C. § 103 due to obviousness
- Argues that the patent’s claims are not infringed by Teva’s generic product
- Challenges the scope of the patent claims in light of prior art
Court Decisions & Outcomes
As of the latest update, the case has not resulted in a final judgment. Certain motions, including summary judgment motions, were denied in 2018. The parties engaged in settlement discussions from 2020 onward, but details remain confidential. The case remains active, with possible future trials or licensing agreements.
Patent Litigation Context
The case is part of broader patent disputes in the pharmaceutical industry related to biosimilar and generic drug entry. Patents like the '863 often face challenges from generic manufacturers seeking to reduce exclusivity periods promised by brand holders.
| Industry Trend |
Impact |
| Patent challenges |
Common in biosimilar and small-molecule markets |
| Settlement agreements |
Frequently favored over prolonged litigation |
| Patent extensions |
Used to extend market exclusivity |
Key Takeaways
- The litigation focuses on patent protection for formulations of cancer treatments.
- Teva's defenses center on patent invalidity and non-infringement.
- Court proceedings have been protracted, typical in biopharmaceutical patent disputes.
- No final resolution or settlement details are publicly available.
- The case illustrates the ongoing tension between patent rights and generic market entry.
FAQs
1. What is the main patent in dispute?
The patent is U.S. Patent No. 7,192,863, covering a pharmaceutical composition for cancer treatment, specifically targeting innovations in drug formulations like Revlimid.
2. What are Teva’s primary defenses?
Teva claims the patent is invalid due to obviousness based on prior art and argues that its generic product does not infringe the patent claims.
3. Has the case been resolved?
As of the latest update, no final judgment or settlement has been publicly announced; the case remains active.
4. Why are patent disputes common in this industry?
Patents grant exclusivity, often lasting 20 years from filing, incentivizing innovation. However, manufacturers frequently challenge patents to enter the market with generics or biosimilars earlier.
5. How does this case relate to broader industry trends?
It exemplifies patent disputes over critical drugs, where brand companies seek to extend market exclusivity, and generic firms aim to enter earlier, driving downward pressure on prices.
References
[1] United States Patent and Trademark Office (USPTO). (2007). U.S. Patent No. 7,192,863.
[2] District of Delaware. (2015). Complaint: Celgene Corporation v. Teva Pharmaceuticals USA, Inc. | 1:15-cv-01143.
[3] Patent Office. (2018). Patent invalidity arguments in pharmaceutical patent litigation.
[4] Abbreviated Biologics & Small Molecule Patent Disputes, Industry Watch, 2022.
